Oligonucleotides inhibiting candida germ tube formation
US5691461A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 18, 1994 |
| Grant date | Nov 25, 1997 |
| Priority date | — |
| Expiry date | Apr 18, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/315
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods are provided for the treatment and diagnosis of Candida infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with at least a portion of a Candida mRNA. Preferred targets are the mRNAs which encode .beta.-tubulin, aspartate protease, actin and chitin synthetase, as well as the mRNA's which encode the ribosomal L25 protein, translation elongation factors 1 and 2 (TEF1 and TEF2), the b subunit of ATPase, and cytochrome P450 lanosterol 14.alpha.-demethylase (L1A1). The oligonucleotides comprise nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3' untranslated sequences, 5' cap, and intron/exon junction of the mRNAs. Methods of treating animals suffering from Candida infection are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.